Radiopharm Theranostics Limited (RADX) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Radiopharm Theranostics L...

    NASDAQ: RADX · Real-Time Price · USD
    6.00
    0.40 (7.14%)
    At close: Sep 05, 2025, 12:46 PM

    Radiopharm Theranostics Income Statement

    Financials in AUD. Fiscal year is July - June.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2023 FY 2022 FY 2021
    Period Ending Jun 30, 2024 Jun 30, 2023 Jun 30, 2022
    Revenue
    		 299.23K 292.36K 8.83K
    Cost of Revenue
    		 n/a n/a n/a
    Gross Profit
    		 299.23K 292.36K 8.83K
    Operating Income
    		 -36.62M -34.51M -19.92M
    Interest Income
    		 50.48K 145.03K n/a
    Pretax Income
    		 -47.85M -34.57M -30.29M
    Net Income
    		 -47.95M -34.61M -30.34M
    Selling & General & Admin
    		 15.22M 13.02M 10.85M
    Research & Development
    		 17.56M 13.8M 4.12M
    Other Expenses
    		 4.14M 7.98M 4.95M
    Operating Expenses
    		 36.92M 34.8M 19.93M
    Interest Expense
    		 642.89K 86.09K 9.35M
    Selling & Marketing Expenses
    		 n/a n/a n/a
    Cost & Expenses
    		 36.92M 34.8M 19.93M
    Income Tax Expense
    		 96.36K 38.01K 44.4K
    Shares Outstanding (Basic)
    		 1.29M 1.02M 1.02M
    Shares Outstanding (Diluted)
    		 1.29M 1.02M 1.02M
    EPS (Basic)
    		 -37.22 -33.95 -29.76
    EPS (Diluted)
    		 -37.22 -33.95 -29.76
    EBITDA
    		 -44.08M -31.19M -17.96M
    EBIT
    		 -47.21M -34.49M -20.94M
    Depreciation & Amortization
    		 3.13M 3.3M 2.98M

    Add to Watchlist